Getting there: Presentation >> Lectures



The tentative titles are provided below and they may change over time:


Kurt Wüthrich, The Scripps Research Institute (USA) & ETH-Zürich (Switzerland)
Opening conference. Structural Biology and Structural Genomics for Rational Drug Design.

Andreas Bender, U. Cambridge, UK
Using Bioactivity Databases and Computer Algorithms for Target Deconvolution and Compound Design.

Ellen L. Berg, BioSeek, EUA
Human Cell Systems Biology for Drug Discovery and Chemical Safety.

Jeffrey Blaney, Genentech, USA
Enabling the Best Structure-Based Design Engine: An Expert Scientist.

Claudio Cavasotto, IBioBA-MPSP, Argentina
Incorporating quantum-mechanical methods in structure-based drug discovery.

Gabriele Cruciani, U. Perugia, Italy
Human Metabolism Prediction: Facts or Fantasy?

Laurent Emmanuel Dardenne, LNCC, Brazil
DockThor: a Brazilian Receptor-Ligand Docking Program.

Federico Gago, U. Alcala, Spain
Progress and Pitfalls in the Modeling and Simulation of Tubulin-Drug Interactions.

Michael Gilson, UCSD, USA
Simulation and informatics for chemical insight and design.

Marcie Ann Glicksman, Harvard NeuroDiscovery Center, USA
The Emergence of Drug Discovery in Academia: Case studies in Neurodegenerative Diseases.

Cristiano Guimaraes, Aché, Brazil
Research, Development & Innovation at Aché.

Catrin Hasselgren, UNM, USA
Informatics and modeling supports drug safety.

Paul Hawkins, OpenEye Scientific Software, Inc., USA
Methodological improvements in docking: are we actually getting better?

Barrie Kellam, U. Nottingham, UK
Illuminating Ligand-Receptor Interactions: New Insights into GPCR Pharmacology using Fluorescent Ligands.

Peter Kenny, IQSC-USP, Brazil
Accident and misadventure in property-based design.

Jerson Lima, UFRJ, Brazil
Prion-Like Neurodegenerative Diseases and Cancer: New Targets to Chemotherapy.

Rui Ferreira A. Moreira, U. Lisboa, Portugal
Chemogenomic approaches to single and dual-stage antimalarial agents.

Tudor I. Oprea, UNM, USA
Drug Repurposing from an Academic Perspective.

Stefan Peukert, U. Novartis, USA
Discovery of the Smoothened Inhibitors LEQ506 and LDE225 for the Treatment of Hedgehog-Dependent Tumors.

Ronaldo Pilli, UNICAMP, Brazil
Synthesis and Biological Activity of Natural Products and Derivatives.

Artur Manoel S. Silva, U. Aveiro, Portugal
New synthetic routes for potential biologically active O- and N-heterocycles.

Antoni Torrens, Esteve, Spain
Discovery of Novel EP1 Ligands for the Treatment of Pain.

Hans P. Wessel, University of Aveiro, Portugal
(Synthetic) Approaches to Lead Identification.

Antony Williams, Royal Society of Chemistry, Reino Unido
Serving the Medicinal Chemistry Community with Royal Society of Chemistry Cheminformatics Platforms.


Cristiano Guimaraes, Ache, Brazil

Claudio Cavasotto, IBioBA-Max Planck Society Partner, Argentina

Jose Daniel Figueroa Villar, IME-RJ, Brazil

Antonia T. do Amaral, IQ-USP, Brazil

Antonio Burtoloso, IQSC-USP, Brazil



"Beyond the Rule of 5"

Confirmed speakers:

Tudor Oprea, UNM, USA

Peter Kenny, IQSC-USP, Brazil


"Virtual Screening: How to do it better and how to know you are doing better"

Confirmed speaker:

Paul Hawkins, OpenEye Scientific Software, Inc., USA


Short course (in portuguese)

Jose Daniel Figueroa Villar, IME-RJ, Brazil
Metodologias de Ressonância Magnética Nuclear em Química Medicinal.


Support & Sponsorship

Getting there

© Copyright 2014 Comitê Organizador do BrazMedChem